Brokerages Set Vera Therapeutics, Inc. (NASDAQ:VERA) Price Target at $74.83

Vera Therapeutics, Inc. (NASDAQ:VERA) has received an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $74.8333.

A number of equities analysts have commented on the company. Bank of America boosted their price objective on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. TD Cowen lifted their price target on Vera Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a report on Friday, December 5th. Wedbush increased their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th.

Insider Buying and Selling at Vera Therapeutics

In other news, Director Patrick G. Enright bought 5,882 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the transaction, the director directly owned 5,882 shares in the company, valued at $249,985. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the transaction, the senior vice president owned 47,839 shares in the company, valued at approximately $1,390,201.34. This represents a 23.87% decrease in their position. The disclosure for this sale is available in the SEC filing. 16.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in VERA. GAMMA Investing LLC boosted its stake in shares of Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares during the last quarter. Quantbot Technologies LP acquired a new position in Vera Therapeutics in the second quarter valued at approximately $51,000. Virtus Investment Advisers LLC boosted its stake in Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after acquiring an additional 539 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares during the period. Finally, Fifth Third Bancorp bought a new stake in shares of Vera Therapeutics during the 2nd quarter valued at $102,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock opened at $48.71 on Tuesday. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of -12.21 and a beta of 1.16. The firm’s 50-day moving average price is $40.18 and its two-hundred day moving average price is $30.19. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period last year, the business earned ($0.85) earnings per share. On average, equities analysts predict that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.